Beijing Advanced Innovation Center for Soft Matter Science and Engineering, State Key Laboratory of Organic-Inorganic Composites, Bionanomaterials & Translational Engineering Laboratory, Beijing Laboratory of Biomedical Materials, Beijing University of Chemical Technology, Beijing, 100029, People's Republic of China.
State Key Laboratory of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100021, People's Republic of China.
ACS Nano. 2020 Mar 24;14(3):2847-2859. doi: 10.1021/acsnano.9b06168. Epub 2020 Mar 12.
Carbon nanomaterials have flourished for cancer therapy for decades. However, their practical applications on clinical bases still pose a challenge to address the dilemma of metabolism . In this study, an attempt is made to design a degradable carbon-silica nanocomposite (CSN) with immunoadjuvant property, which could undergo an enzyme-free degradation process into small particles (∼5 nm) and facilitate its clinical application. CSN harbors photothermal and photodynamic properties and as an immunoadjuvant would help to generate tumor-associated antigens and mature dendritic cells (DCs). Potent antitumor effects have been achieved in both 4T1 and patient-derived xenograft tumor models with tumor inhibition efficiencies of 93.2% and 92.5%, respectively. We believe that this strategy will benefit the possible clinical translation and carbon-silica-nanomaterial-based cancer therapy.
碳纳米材料在癌症治疗方面已经活跃了几十年。然而，它们在临床基础上的实际应用仍然面临着解决代谢难题的挑战。在这项研究中，我们试图设计一种具有免疫佐剂特性的可降解碳-硅纳米复合材料（CSN），它可以在没有酶的情况下降解成小颗粒（约 5nm），从而促进其临床应用。CSN 具有光热和光动力特性，作为免疫佐剂可以帮助产生肿瘤相关抗原和成熟的树突状细胞（DCs）。在 4T1 和患者来源的异种移植肿瘤模型中都取得了强大的抗肿瘤效果，肿瘤抑制效率分别为 93.2%和 92.5%。我们相信，这种策略将有利于碳-硅纳米材料为基础的癌症治疗的可能临床转化。
